Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post Concussion Syndrome (PCS) and TBI/Post-Traumatic Stress Disorder (PTSD)

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (201 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: injurysyndrometime ofdisorderhistory of
  Phrases that lowered it: moderatemildtrialgoodhigh
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 4 (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Design: single group (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 0 (lowers risk) · Drug's FDA history
• Maximum age: 65 (lowers risk) · Who can join
• Disease area, neurology: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Hyperbaric Oxygen Therapy (HBO2) for Persistent Post-concussive Symptoms After Mild Traumatic Brain Injury (mTBI) NCT01306968 · started 2011 · scored riskier than 72% of active trials completed
• Hyperbaric Oxygen Effects on Persistent Post-concussive Symptoms NCT05173818 · started 2022 · scored riskier than 73% of active trials completed
• Hyperbaric Treatment of Traumatic Brain Injury (TBI) NCT01847755 · started 2013 · scored riskier than 90% of active trials completed
• Treatment of U.S. Veterans With Mild Traumatic Brain Injury With Hyperbaric Oxygen Therapy NCT06665633 · started 2021 · scored riskier than 87% of active trials completed
• mTBI Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms NCT01611194 · started 2012 · scored riskier than 70% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.